2017 | 2016 | 2015 | 2014
DateTitle 
06/13/17Excellagen® Receives USPTO Notice Of Allowance For A New Patent Application Covering Blood Platelet Activation & Endogeneous Growth Factor Release For Wound Repair And Tissue RegenerationPrinter Friendly Version
06/12/17Angionetics To Present At Marcum 2017 MicroCap conference In New York CityPrinter Friendly Version
06/05/17Angionetics To Present At Globalization Of Research And Industrialization Of Bio-Medicine Summit 2017 In Shenzhen, ChinaPrinter Friendly Version
02/09/17Angionetics To Present At The Biotechnology Industry Organization CEO & Investor Conference At The Waldorf Astoria New York CityPrinter Friendly Version
02/07/17FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart DiseasePrinter Friendly Version
01/09/17Angionetics Research Head Authors Scientific American Article on Therapeutic Angiogenesis as Potential New Treatment Approach for Ischemic Heart DiseasePrinter Friendly Version
01/03/17Angionetics To Present At Two San Francisco-Based Healthcare Conferences: The Biotech Showcase 2017 And The 10th Annual OneMed ForumPrinter Friendly Version
12/14/16Taxus Cardium Announces Two Director Retirements Following A Decade Of Distinguished ServicePrinter Friendly Version
09/12/16Angionetics' Generx® [Ad5FGF-4] Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery DiseasePrinter Friendly Version
07/11/16Angionetics & A Huapont Life Sciences Affiliate Enter Agreement To Commercialize Generx® Angiogenic Gene Therapy Product Candidate For Ischemic Heart Disease In ChinaPrinter Friendly Version
07/11/16Angionetics & A Huapont Life Sciences (China) Affiliate Enter Into Equity Financing Agreement For Phase 3 Clinical Development Of Generx Gene Therapy For Ischemic Heart DiseasePrinter Friendly Version
05/26/15Angionetics To Present At 2015 LD Micro Invitational Investor Conference On Business And Generx® Phase 3 Clinical Development ActivitiesPrinter Friendly Version
05/15/15Angionetics Presents at the 2015 American Society of Gene & Cell Therapy Conference On Generx® Angiogenic Phase 3 Gene Therapy ProgramPrinter Friendly Version
05/11/15Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx® Clinical Development ActivitiesPrinter Friendly Version
04/13/15Angionetics Initial Equity Funding to Advance as Independent Company to Develop and Commercialize Phase 3 Generx® Gene Therapy Product CandidatePrinter Friendly Version
04/07/15Taxus Cardium Announces Agreement With Dr. Reddy's Laboratories To Co-Develop, Market & Sell Generx Angiogenic Microvascular Gene Therapy In Certain International MarketsPrinter Friendly Version
01/27/15Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy ForumPrinter Friendly Version
01/15/15Taxus Cardium Elects Three New Board Members Including PRC Strategic Investor Jiayue Zhang, John Wallace, U.S. Equity Trading Services Executive, And Wei-Wei Zhang, International Gene Therapy PioneerPrinter Friendly Version
11/20/14Taxus Cardium Reports On Third Quarter 2014 Results And Corporate Development ActivitiesPrinter Friendly Version
09/03/14Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York CityPrinter Friendly Version
08/13/14Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'Printer Friendly Version
08/13/14Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular PharmacologyPrinter Friendly Version
08/12/14Taxus Cardium Presents Second Quarter 2014 Financial Results and Recent DevelopmentsPrinter Friendly Version
06/24/14Cardium Announces Positive Interim Phase 3 Clinical Data Showing Significant Efficacy of Generx® Angiogenic Gene Therapy for Myocardial Ischemia Due to Coronary Artery Disease at the 2014 BIO International ConventionPrinter Friendly Version
06/12/14Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International ConventionPrinter Friendly Version
05/22/14Taxus Cardium To Present On Advanced Regenerative Therapeutics Development Activities At Marcum Microcap ConferencePrinter Friendly Version
05/12/14Taxus Cardium’s Excellagen® Selected For Use With Stem Cells In Eu-Funded Human Clinical StudyPrinter Friendly Version
04/15/14Taxus Cardium Presents Year-End 2013 Financial Results And Recent DevelopmentsPrinter Friendly Version
03/17/14Cardium Becomes Taxus Cardium Pharmaceuticals Group In Connection With Strategic Collaboration And Funding With Shanxi Taxus PharmaceuticalsPrinter Friendly Version
03/03/14Cardium Announces Strategic Collaboration And Funding With Taxus Pharmaceuticals To Support Commercial Development of Advanced Regenerative Therapeutics Printer Friendly Version
01/27/14Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical FindingsPrinter Friendly Version
01/24/14Cardium Common Stock To Begin Trading On The OTCQB MarketPrinter Friendly Version
12/31/13Cardium Reports On Advancement Of Generx And Excellagen Biologic Products And Corporate DevelopmentsPrinter Friendly Version
12/20/13Cardium Provides Update On Exchange ListingPrinter Friendly Version
12/04/13Cardium's Excellagen Assigned Q Code For Product ReimbursementPrinter Friendly Version
12/03/13LifeAgain's Bluemetric Select Life Insurance Now Offered At Lifequotes.comPrinter Friendly Version
11/19/13Cardium Reports On Third Quarter 2013 Financial Results And Recent Business DevelopmentsPrinter Friendly Version
11/18/13Cardium's To Go Brands Acquired By Cell-nique And Healthy Brands CollectivePrinter Friendly Version
11/08/13Cardium Announces Publication On Use Of Excellagen For Managing Chronic Pressure Ulcers In Elderly PatientsPrinter Friendly Version
10/07/13Cardium Provides Update On Exchange ListingPrinter Friendly Version
09/27/13Unusual Trading Activity In Cardium Common StockPrinter Friendly Version
09/20/13LifeAgain Announces Recognition Of National Prostate Cancer Awareness MonthPrinter Friendly Version
09/19/13LifeAgain Supports Life Insurance Awareness MonthPrinter Friendly Version
09/16/13Cardium's LifeAgain Launches First Life Insurance Program Developed For Men With Active Localized Prostate CancerPrinter Friendly Version
08/26/13Cardium's LifeAgain Announces Commercialization Agreement With AgencyONE Based On Advanced Medical Data Analytics Platform TechnologyPrinter Friendly Version
08/14/13Cardium Reports On Second Quarter 2013 Financial Results And Recent Business DevelopmentsPrinter Friendly Version
08/12/13Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem CellsPrinter Friendly Version
08/07/13Cardium Announces Excellagen Distribution Agreement With Kasiak For Germany And SwitzerlandPrinter Friendly Version
08/06/13Cardium Reports On New Excellagen-Based Stromal Cell Research For Wound Healing With Orbsen Therapeutics Under European FP7 REDDSTAR Diabetes InitiativePrinter Friendly Version
08/05/13Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional PropertiesPrinter Friendly Version
08/01/13Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical FacilitiesPrinter Friendly Version
07/19/13Cardium Completes Preferred Stock FinancingPrinter Friendly Version
07/18/13Cardium Announces Reverse Stock SplitPrinter Friendly Version
07/02/13Cardium Announces Final Voting Results Of Annual Meeting Of StockholdersPrinter Friendly Version
06/21/13Cardium Announces Temporary Adjournment of Annual Meeting To Be Reconvened On July 2, 2013Printer Friendly Version
06/06/13Cardium Announces Initial Voting Results And Temporary Adjournment of Annual Meeting To Be Reconvened On June 21, 2013Printer Friendly Version
05/28/13Cardium Announces Favorable Recommendations From ISS And Glass Lewis For Annual Meeting ProposalsPrinter Friendly Version
05/15/13Cardium Presents First Quarter 2013 Financial Results And Reports On Recent DevelopmentsPrinter Friendly Version
05/02/13Cardium Announces Generx Publication In Molecular TherapyPrinter Friendly Version
04/30/13Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 MeetingPrinter Friendly Version
04/05/13Cardium Presents Year-End 2012 Financial Results And Recent DevelopmentsPrinter Friendly Version
04/05/13Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing CompliancePrinter Friendly Version
03/14/13Cardium Receives ISO Certification for ExcellagenPrinter Friendly Version
03/13/13Cardium's To Go Brands® to Launch Expanded VitaRocks® kids Vitamin Line With New Retail DistributionPrinter Friendly Version
02/12/13Cardium's Excellagen® Awarded American Podiatric Medical Association Seal of ApprovalPrinter Friendly Version
01/29/13Cardium Announces Presentation at The 2013 Cell & Gene Therapy ForumPrinter Friendly Version
01/16/13Cardium Exchange Listing Compliance Plan Accepted by NYSE MKTPrinter Friendly Version
01/04/13Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium InitiativesPrinter Friendly Version
01/03/13Cardium Announces Sales and Distribution Agreement With Academy Medical to Promote Excellagen Clinical Adoption by U.S. Government Medical ProvidersPrinter Friendly Version
12/06/12Cardium Reports On NYSE MKT Noncompliance Notice And Compliance PlanPrinter Friendly Version
11/19/12Cardium Announces Patent Award For Rights To Cardiovascular Gene Therapy For The Treatment Of Heart DiseasePrinter Friendly Version
11/14/12Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent DevelopmentsPrinter Friendly Version
11/13/12Cardium Announces Excellagen Poster Presentations At Desert Foot 9th Annual High Risk Diabetic Foot ConferencePrinter Friendly Version
11/06/12European Union's First Gene Therapy Approval Represents Major Advancement For IndustryPrinter Friendly Version
10/01/12Cardium Announces the Acquisition of To Go BrandsPrinter Friendly Version
09/24/12Cardium To Present At 2012 Noble Financial Life Sciences Investor ConferencePrinter Friendly Version
09/20/12Cardium Announces Medical Advisory Board To Support Excellagen Advanced Wound Care ProductPrinter Friendly Version
08/30/12Cardium to Present at the Rodman & Renshaw Annual 2012 Healthcare Investment ConferencePrinter Friendly Version
08/14/12Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent DevelopmentsPrinter Friendly Version
08/01/12Cardium's Excellagen® Named As Top 10 Innovation In PodiatryPrinter Friendly Version
07/26/12Published Findings In Human Gene Therapy Methods Journal Demonstrate Cardium's New Catheter-Based Method Significantly Boosts Gene Delivery To The HeartPrinter Friendly Version
06/19/12Cardium Announces Launch Of New MedPodium Neo-Chill Nutra-App® At NACDS Marketplace 2012Printer Friendly Version
06/14/12Cardium To Present At The Marcum MicroCap ConferencePrinter Friendly Version
06/12/12Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian FederationPrinter Friendly Version
06/05/12AMRI Burlington Contracted As Aseptic Fill Manufacturer for Market Introduction of Excellagen® Wound Care ProductPrinter Friendly Version
05/17/12Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life SciencesPrinter Friendly Version
05/16/12Cardium Reports New Catheter-Based Methods Significantly Boost Cardiac Gene Delivery In Late-Breaking Presentation at 2012 American Society of Gene & Cell Therapy MeetingPrinter Friendly Version
05/15/12Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market ExpansionPrinter Friendly Version
05/15/12Cardium Presents First Quarter 2012 Financial Results and Recent DevelopmentsPrinter Friendly Version
04/19/12Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound CarePrinter Friendly Version
03/30/12Cardium Presents Fourth Quarter and Year-End 2011 Financial Results and Recent DevelopmentsPrinter Friendly Version
03/30/12Cardium Announces U.S. Market Introduction of Excellagen™Printer Friendly Version
03/21/12RevNutrition.com to Carry MedPodium Nutra-Apps® BrandPrinter Friendly Version
03/20/12Cardium Initiates Generx® Phase 3 Clinical Registration StudyPrinter Friendly Version
03/14/12Cardium Partners With NPI, InHealth MediaPrinter Friendly Version
02/16/12Cardium Announces Closing of $5.0 Million Equity FinancingPrinter Friendly Version
02/13/12Cardium Announces $5.0 Million Financing With Institutional InvestorsPrinter Friendly Version
01/30/12Cardium Presents New Generx Findings at 2012 Annual Gene and Cell Therapy ForumPrinter Friendly Version
01/06/12Cardium Regains Listing Compliance With NYSE AmexPrinter Friendly Version
01/05/12Cardium Announces First International Marketing and Distribution Agreement for Commercialization of Excellagen(TM) in South KoreaPrinter Friendly Version
01/04/12Cardium to Present at Upcoming Investor ConferencesPrinter Friendly Version
01/03/12Cardium Reports on Renewed Compliance With NYSE Amex Exchange Listing GuidelinesPrinter Friendly Version
12/21/11Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical FoodsPrinter Friendly Version
12/13/11Cardium Announces MedPodium Neo-Energy(TM) and Neo-Carb Bloc(TM)Printer Friendly Version
11/14/11Cardium Presents Third Quarter 2011 Financial Results and Reports on Near-Term MilestonesPrinter Friendly Version
10/10/11Cardium Announces FDA 510(k) Clearance for U.S. Marketing and Sale of Excellagen Formulated Collagen Topical Gel for Diabetic Foot Ulcers, Pressure Ulcers and Other Dermal WoundsPrinter Friendly Version
09/27/11Cardium Reports Exchange Compliance Plan Accepted by NYSE AmexPrinter Friendly Version
09/01/11Cardium to Present at the Rodman & Renshaw Annual Healthcare Investment ConferencePrinter Friendly Version
08/29/11Cardium Provides Update on Exchange Listing and Related Business MattersPrinter Friendly Version
08/26/11Cardium to Present at Southern California Investor ConferencePrinter Friendly Version
08/25/11Cardium Announces Market Introduction of New D-Sorb(TM) to Expand the MedPodium Healthy Lifestyle Product LinePrinter Friendly Version
08/18/11Cardium Announces Receipt of $1.1 Million in Funds from Philips' Acquisition of Innercool TherapiesPrinter Friendly Version
08/15/11Cardium Presents Second Quarter 2011 Financial Results and Reports on Near-Term MilestonesPrinter Friendly Version
08/02/11Cardium Provides Update on Excellagen 510(K) Registration and Commercialization PlansPrinter Friendly Version
07/28/11Cardium Reports on Transdel TransactionPrinter Friendly Version
07/12/11Cardium Announces Market Introduction of New Alena(TM) Clinical Strength Carb Blocker to Expand the MedPodium Healthy Lifestyle Product LinePrinter Friendly Version
06/27/11Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business AssetsPrinter Friendly Version
06/22/11Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian FederationPrinter Friendly Version
06/15/11Generx DNA-Based Angiogenic Therapy Receives Russian Ministry of Health Clearance for Late-Stage Registration Clinical Study for Coronary Artery DiseasePrinter Friendly Version
06/13/11Cardium Announces Launch of Cerex(TM) to Support Cognitive Performance Expanding the MedPodium Healthy Lifestyle Product LinePrinter Friendly Version
05/16/11Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term MilestonesPrinter Friendly Version
03/31/11Cardium Presents Fourth Quarter and Year-End 2010 Financial Results and Recent DevelopmentsPrinter Friendly Version
03/08/11Positive Findings From Excellagen Matrix Clinical Study Published in Peer-Reviewed Journal Wound Repair and RegenerationPrinter Friendly Version
01/24/11Cardium's Exchange Listing Compliance Plan Accepted by NYSE AmexPrinter Friendly Version
01/18/11Cardium Announces Plans to Introduce Cerex(TM) to Support Cognitive Performance Expanding the MedPodium(TM) Modern Lifestyle Product LinePrinter Friendly Version
01/06/11Cardium to Present at OneMedForum San Francisco 2011 ConferencePrinter Friendly Version
12/28/10Cardium Reports Excellagen Matrix Clinical Study Results Accepted for Publication by Peer-Reviewed Journal, and Updates Product PlansPrinter Friendly Version
12/02/10Cardium Reports on Exchange Listing Deficiency and Compliance PlanPrinter Friendly Version
11/29/10Cardium Announces Market Launch of Linee(TM) - A Scientific Approach to Weight ManagementPrinter Friendly Version
11/18/10Cardium Announces Co-Development and Strategic Licensing Agreement with BioZone Laboratories for Expansion of MedPodium PortfolioPrinter Friendly Version
11/15/10Cardium Reports on Presentation at American Heart Association Meeting Relating to Gene Delivery to the Heart and Generx Clinical DevelopmentPrinter Friendly Version
11/09/10Cardium Reports on Third Quarter 2010 Financial Results and Recent DevelopmentsPrinter Friendly Version
11/08/10Cardium to Present at the LifeTech Capital Miami Medical Investors ConferencePrinter Friendly Version
11/04/10Cardium Announces Launch of Its MedPodium Healthy Lifestyle Product Initiative and New Web BoutiquePrinter Friendly Version
11/03/10Cardium Awarded Grant Under Qualifying Therapeutic Discovery Project ProgramPrinter Friendly Version
10/13/10Cardium Announces New Research Findings: Excellagen Product Candidate Activates Platelet Release of PDGF, an Important Growth Factor Fundamental to the Wound Healing ProcessPrinter Friendly Version
09/29/10Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product PortfolioPrinter Friendly Version
09/20/10Cardium to Present at 10th Annual Biotech in Europe Investor ForumPrinter Friendly Version
09/09/10Cardium to Present at the Rodman & Renshaw 12th Annual Healthcare Investment ConferencePrinter Friendly Version
09/09/10Cardium Announces Appexium(TM), a New Weight Loss Management Dietary Supplement to Expand MedPodium's Healthy Lifestyle Product InitiativePrinter Friendly Version
09/09/10Cardium to Present at the Rodman & Renshaw 12th Annual Healthcare Investment ConferencePrinter Friendly Version
08/09/10Cardium Reports on Second Quarter 2010 Financial Results and Recent DevelopmentsPrinter Friendly Version
07/07/10Cardium Regains Listing Compliance With NYSE AmexPrinter Friendly Version
06/23/10Cardium Reports on Compliance of NYSE Amex Exchange Listing GuidelinesPrinter Friendly Version
06/14/10Cardium Announces Dominique Dawes, Olympic Champion, as Web-Based Spokesperson for New MedPodium Podiatry-Focused Advanced Skin Care Product LinePrinter Friendly Version
06/10/10Cardium Announces Master Services Agreement With bioRASI for Planned Late-Stage Clinical Study and Commercialization Activities for Generx Product Candidate in International MarketsPrinter Friendly Version
06/08/10Cardium Announces Collagen Supply Agreement with Devro Medical for Planned Market Launch of Excellagen Product Candidate and Reports on Further Positive Healing EffectsPrinter Friendly Version
05/10/10Cardium Reports on First Quarter 2010 Financial Results and Recent DevelopmentsPrinter Friendly Version
05/07/10Cardium to Present at MDB Capital Group's 2010 Bright Lights ConferencePrinter Friendly Version
03/16/10Cardium Reports on Fourth Quarter and Year-End 2009 Financial Results and Recent DevelopmentsPrinter Friendly Version
03/15/10Cardium Announces Closing of $11.3 Million in Registered Direct Equity OfferingPrinter Friendly Version
03/09/10Cardium Reports on Registered Direct OfferingPrinter Friendly Version
03/08/10Cardium's Exchange Listing Compliance Plan Accepted by NYSE AMEXPrinter Friendly Version
02/16/10Cardium Announces Agreement With bioRASI to Advance and Broaden Clinical Development of Generx Product CandidatePrinter Friendly Version
01/26/10Cardium Provides Update on Commercial Development Plans for Generx Angiogenic Therapy for Heart Disease at 2010 Cell & Gene Therapy ForumPrinter Friendly Version
01/05/10Cardium to Launch MedPodium(TM) Product Line Initially Covering Six New Advanced Foot Care Products for Podiatry Patients to Complement the Excellagen PlatformPrinter Friendly Version
01/04/10Cardium Reports on Exchange Listing With NYSE AMEXPrinter Friendly Version
12/16/09Cardium Reports on Recent Norwegian Study Revealing That History of Foot Ulcers Is a Significant Predictor of Mortality in Diabetic PatientsPrinter Friendly Version
12/14/09Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical DevelopmentPrinter Friendly Version
12/03/09Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal WoundsPrinter Friendly Version
11/10/09Cardium Reports on Third Quarter 2009 Financial Results and Recent DevelopmentsPrinter Friendly Version
11/02/09Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical WoundsPrinter Friendly Version
10/20/09Cardium Completes $6.0 Million Registered Direct OfferingPrinter Friendly Version
10/15/09Cardium Announces $6.0 Million Registered Direct OfferingPrinter Friendly Version
10/15/09Positive Findings from Excellarate(TM) Phase 1/2 Clinical Study Published in Journal of Wound Repair and RegenerationPrinter Friendly Version
10/14/09Cardium Announces Commercial Development of Excellagen(TM) a Customized Collagen-Based Topical Gel for Initial Use as an Adjunct to Surgical Debridement in Patients With Diabetic Foot UlcersPrinter Friendly Version
10/14/09Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate(TM) Topical Gel for Non-Healing Diabetic Foot Ulcers and Plans for Phase 3 ProgramPrinter Friendly Version
10/01/09Cardium Announces Planned Release of Data from Matrix Excellarate Phase 2b Clinical Study and Acceptance of Phase 1 / 2 Study for Publication in Wound Repair and RegenerationPrinter Friendly Version
09/14/09Cardium Announces $4.5 Million Common Stock Private PlacementPrinter Friendly Version
09/14/09Scientific Journal Gene Therapy Reports That Cardium's Gene Activated Matrix Technology Accelerates Periodontal Tissue RegenerationPrinter Friendly Version
08/27/09Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare ProvidersPrinter Friendly Version
08/25/09Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical StudyPrinter Friendly Version
08/11/09Cardium Reports on Second Quarter 2009 Financial Results and Recent DevelopmentsPrinter Friendly Version
07/30/09Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth FactorsPrinter Friendly Version
07/28/09Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair ApplicationsPrinter Friendly Version
07/27/09Cardium Regains Listing Compliance with NYSE AmexPrinter Friendly Version
07/24/09Cardium Completes Sale of InnerCool Therapies Business to Royal Philips ElectronicsPrinter Friendly Version
07/15/09Cardium's InnerCool Therapies Business to Be Acquired By Royal Philips ElectronicsPrinter Friendly Version
06/17/09Cardium Receives Preliminary Notification of Inclusion in the Russell 3000(R) Index and Russell Global(R) IndexPrinter Friendly Version
05/28/09Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual MeetingPrinter Friendly Version
05/12/09Cardium Announces Conference Call and Webcast to Review Recent Developments and Future Plans for the Excellarate(TM) Clinical Development ProgramPrinter Friendly Version
05/11/09Cardium Reports on First Quarter 2009 Financial Results and Recent DevelopmentsPrinter Friendly Version
05/07/09Cardium Reports on New Excellarate(TM) Product Formulations to Expand Commercialization Potential Into Multiple Wound Healing ApplicationsPrinter Friendly Version
05/06/09Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot UlcersPrinter Friendly Version
04/15/09Cardium Provides Update Regarding Exchange Listing Compliance Plan Accepted by NYSE AmexPrinter Friendly Version
03/31/09Cardium's InnerCool Announces Journal of Neurotrauma Highlights Hypothermia Therapy's Role in Post Cardiac Arrest, and Traumatic Brain and Spinal Cord Injury PatientsPrinter Friendly Version
03/27/09Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart AttackPrinter Friendly Version
03/26/09Cardium Reports on Recent Highlights, Financial Results and 2009 OutlookPrinter Friendly Version
03/09/09Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in UrologyPrinter Friendly Version
03/05/09Cardium Completes $3.5 Million Credit FacilityPrinter Friendly Version
02/19/09Cardium's Exchange Listing Compliance Plan Accepted by NYSE Alternext USPrinter Friendly Version
02/12/09TV News Coverage Reports on InnerCool's CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, ChicagoPrinter Friendly Version
02/03/09Gene Therapy Field Advances With Important Clinical Findings Reported in the New England Journal of MedicinePrinter Friendly Version
01/29/09Cardium's InnerCool Reports on Expanding Use of Therapeutic HypothermiaPrinter Friendly Version
01/27/09Cardium's InnerCool Announces Launch of New Enhanced WebsitePrinter Friendly Version
01/26/09Cardium Announces Retirement of DirectorPrinter Friendly Version
01/14/09International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCool's New Investigational UroCool SystemPrinter Friendly Version
12/30/08Cardium Reports on Exchange Listing With NYSE Alternext USPrinter Friendly Version
12/16/08Cardium's InnerCool Announces First Patient Treated With New Tissue-Specific UroCool(TM) System in Robotic-Assisted Prostate Surgery StudyPrinter Friendly Version
12/15/08Cardium's InnerCool Awarded U.S. Supplier Agreement With Novation LLCPrinter Friendly Version
12/05/08Cardium Reports on New York City's Adoption of Therapeutic Cooling Protocols for Cardiac Arrest PatientsPrinter Friendly Version
12/03/08Cardium Announces Investor Presentation and Corporate Update WebcastPrinter Friendly Version
11/11/08Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate SurgeriesPrinter Friendly Version
11/10/08Cardium Completes $6.0 Million FinancingPrinter Friendly Version
11/10/08Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating UnitsPrinter Friendly Version
10/20/08Cardium Announces FDA 510(K) Clearance of InnerCool's RapidBlue(TM) Endovascular SystemPrinter Friendly Version
08/11/08Cardium Reports on Second Quarter 2008 Highlights and Financial ResultsPrinter Friendly Version
07/28/08Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development ActivitiesPrinter Friendly Version
07/21/08Cardium Completes Registered Direct InvestmentPrinter Friendly Version
07/14/08Cardium Announces InnerCool's New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certificationPrinter Friendly Version
06/30/08Cardium Announces Follow-On Direct Investment by Institutional InvestorPrinter Friendly Version
06/24/08Cardium Selected for Inclusion in Russell Microcap IndexPrinter Friendly Version
06/19/08Cardium's InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation SystemsPrinter Friendly Version
06/11/08Cardium Launches New AWARE Clinical Study WebsitePrinter Friendly Version
05/27/08Cardium and Tissue Repair Company Launch New Matrix Study WebsitePrinter Friendly Version
05/23/08Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008Printer Friendly Version
05/09/08Cardium Reports on First Quarter 2008 Highlights and Financial ResultsPrinter Friendly Version
05/01/08Richard A. Schatz, M.D. Joins Cardium's Scientific Advisory BoardPrinter Friendly Version
04/29/08Cardium Reports on Science Channel Series Featuring InnerCool's Endovascular Cooling During Brain Surgery at Stanford UniversityPrinter Friendly Version
04/22/08Cardium Announces InnerCool's Endovascular Cooling to be Featured on Science Channel's Series 'Cool Stuff: How It Works'Printer Friendly Version
04/15/08Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart AttackPrinter Friendly Version
04/01/08Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation SystemsPrinter Friendly Version
03/19/08Cardium's InnerCool Therapies Unit Announces Australian Distribution Agreement for CoolBlue and Rapid Blue SystemsPrinter Friendly Version
03/17/08Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.Printer Friendly Version
03/14/08Cardium Reports on Recent Highlights and Financial ResultsPrinter Friendly Version
03/11/08Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary InfusionPrinter Friendly Version
02/01/08Cardium Completes $5.3 Million Registered Direct OfferingPrinter Friendly Version
01/31/08Cardium Announces $5.3 Million Registered Direct OfferingPrinter Friendly Version